The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has been proposed to predict how well an antiretroviral regimen treats CNS infection. Fabbiani et al. report that ‘correcting’ the CPE rank of each drug in an individual's regimen for the results of genotypic susceptibility (the CPE-GSS score) results in better ability to predict whether the regimen will improve cognition. The CPE-GSS score may help us better understand the aetiology of HIV-associated cognitive impairment. Whether it will be useful in the management of individual patients requires further study.
References
1.
NaviaB.A., JordanB.D., PriceR.W.The AIDS dementia complex: I. Clinical features.Ann Neurol1986; 19: 517–524.
2.
PriceR.W., BrewB., SidtisJ., RosenblumM., ScheckA.C., ClearyP.The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.Science1988; 239: 586–592.
3.
ChiesiA., VellaS., DallyL.G.Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group.J Acquir Immune Defic Syndr Hum Retrovirol1996; 11: 39–44.
4.
McArthurJ.C., HooverD.R., BacellarH.Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.Neurology1993; 43: 2245–2252.
5.
AntinoriA., ArendtG., BeckerJ.T.Updated research nosology for HIV-associated neurocognitive disorders.Neurology2007; 69: 1789–1799.
6.
HeatonR.K., CliffordD.B., FranklinD.R.Jr.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.Neurology2010; 75: 2087–2096.
7.
SimioniS., CavassiniM., AnnoniJ.M.Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.AIDS2010; 24: 1243–1250.
8.
BonnetF., AmievaH., MarquantF.Cognitive disorders in HIV-infected patients: are they HIV-related?AIDS2013; 27: 391–400.
9.
EllisR.J., BadieeJ., VaidaF.CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.AIDS2011; 25: 1747–1751.
WendelkenL.A., ValcourV.Impact of HIV and aging on neuropsychological function.J Neurovirol2012; 18: 256–263.
12.
WrightE.J., GrundB., RobertsonK.Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.Neurology2010; 75: 864–873.
13.
FogelG.B., LamersS.L., LevineA.J.Factors related to HIV-associated neurocognitive impairment differ with age.J Neurovirol2015; 21: 56–65.
14.
SattlerF.R., HeJ., LetendreS.Abdominal obesity contributes to neurocognitive impairment in HIV infected patients with increased inflammation and immune activation.J Acquir Immune Defic Syndr2015; 68: 281–288.
15.
UnderwoodJ., RobertsonK.R., WinstonA.Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?AIDS2015; 29: 253–261.
16.
CanigliaE.C., CainL.E., JusticeA.Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.Neurology2014; 83: 134–141.
17.
EdénA., FuchsD., HagbergL.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.J Infect Dis2010; 202: 1819–1825.
18.
CanestriA., LescureF.X., JaureguiberryS.Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.Clin Infect Dis2010; 50: 773–778.
19.
LetendreS., Marquie-BeckJ., CapparelliE.Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.Arch Neurol2008; 65: 65–70.
20.
LetendreS.Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.Top Antivir Med2011; 19: 137–142.
21.
CysiqueL.A., WatersE.K., BrewB.J.Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.BMC Neurol2011; 11: 148.
22.
EllisR.J., LetendreS., VaidaF.Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.Clin Infect Dis2014; 58: 1015–1022.
23.
CiccarelliN., FabbianiM., ColafigliM.Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.Antivir Ther2013; 18: 153–160.
24.
ShikumaC.M., NakamotoB., ShiramizuB.Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.Antivir Ther2012; 17: 1233–1242.
25.
GrayL.R., TachedjianG., EllettA.M.The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.PLoS ONE2013; 8: e62196.
26.
FabbianiM., GrimaP., MilaniniB.Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.Antivir Ther2014; doi: 10.3851/IMP2926.
